Stuart Poulton

CIK: 0001942597

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (57.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KPTI

Karyopharm Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

KPTI
Karyopharm Therapeutics Inc.
Jul 28, 2026
Sale(S)
Direct
189 shares at avg. $7.10$1K
KPTI
Karyopharm Therapeutics Inc.
May 14, 2026
Sale(S)
Direct
403 shares at avg. $9.50$4K
KPTI
Karyopharm Therapeutics Inc.
May 13, 2026
Award(A)
Direct
896 shares-
KPTI
Karyopharm Therapeutics Inc.
Mar 2, 2026
Sale(S)
Direct
5.1K shares at avg. $9.41$48K
KPTI
Karyopharm Therapeutics Inc.
Feb 17, 2026
Sale(S)
Direct
378 shares at avg. $8.63$3K
KPTI
Karyopharm Therapeutics Inc.
Jan 31, 2026
Award(A)
Direct
32.4K shares-
KPTI
Karyopharm Therapeutics Inc.
Oct 15, 2025
Award(A)
Direct
39.7K shares-
KPTI
Karyopharm Therapeutics Inc.
Sep 15, 2025
Sale(S)
Direct
401 shares at avg. $6.43$3K
KPTI
Karyopharm Therapeutics Inc.
Sep 12, 2025
Award(A)
Direct
888 shares-
KPTI
Karyopharm Therapeutics Inc.
Jul 29, 2025
Sale(S)
Direct
191 shares at avg. $4.37$834.67
KPTI
Karyopharm Therapeutics Inc.
Mar 4, 2025
Sale(S)
Direct
3.5K shares at avg. $6.29$22K
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
4.6K shares-
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
5K shares-
KPTI
Karyopharm Therapeutics Inc.
Feb 18, 2025
Sale(S)
Direct
5.9K shares at avg. $0.63$4K

		Type	Shares	Price		Ownership
Jul 28, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	189	$7.10	$1,342	Direct
May 14, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	403	$9.50	$3,829	Direct
May 13, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	896	-	$0	Direct
Mar 2, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	5,101	$9.41	$47,998	Direct
Feb 17, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	378	$8.63	$3,262	Direct
Jan 31, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	32,415	-	$0	Direct
Oct 15, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	39,682	-	-	Direct
Sep 15, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	401	$6.43	$2,578	Direct
Sep 12, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	888	-	-	Direct
Jul 29, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	191	$4.37	$835	Direct
Mar 4, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	3,548	$6.29	$22,317	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	4,583	-	-	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	5,000	-	-	Direct
Feb 18, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	5,914	$0.63	$3,726	Direct

1-14 of 14 transactions

About Poulton Stuart

Poulton Stuart (SEC CIK 0001942597) files insider reports with the SEC as EVP, Chief Development Officer of Karyopharm Therapeutics Inc. (KPTI).

Signal8 holds 11 ownership filings by Poulton Stuart, all Form 4s, filed between Feb 19, 2025 and Jul 30, 2026. Those filings report 14 transactions, from Feb 18, 2025 to Jul 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Poulton Stuart's filings is in NEWTON, MA.

Recent filings by Poulton Stuart

Jul 28, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 14, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 13, 2026: Grant or award of KPTI shares (Form 4, code A).
Mar 2, 2026: Open-market sale of KPTI shares (Form 4, code S).
Feb 17, 2026: Open-market sale of KPTI shares (Form 4, code S).

Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)

Abate Kristin, Chief Accounting Officer
Oliger Christy J., Director
PAKIANATHAN DEEPIKA, Director
Schor Chen, Director
Su Zhen, Director
BOHLIN GAREN G, Director

How to read Form 4 transaction codes